Chang, Tse Wen 張子文

ChangTW 6x7客座講座


twchanggateEmail
 

 

 

EDUCATION AND POSITIONS HELD:

  • B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972
  • Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977
  • Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980
  • Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981
  • Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985
  • Professor of Molecular Virology, Baylor College of Medicine, 1986-1991
  • Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston
  • Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University
  • President, Development Center for Biotechnology, Taipei, 2000-2003
  • Distinguished Professor, Genomics Research Center, Academia Sinica, 2006-2015
  • Distinguished Visiting Chair, Genomics Research Center, Academia Sinica, 2016-present

HONORS:

  • Foundation for the Advancement of Outstanding Scholarship Award, 1997-2002
  • Appointed Science and Technology Advisor of the Executive Yuan, 2002-2006
  • Xolair (Chang's anti-IgE invention) approved by FDA, USA, 2003
  • Appointed Tsing Hua Professor of Life Science, 2003-2006
  • "Honorary Fellow Award" from American College of Allergy, Asthma, and Immunology (ACAAI), 2004
  • Nature Biotechnology's shortlist of personalities who made the most significant contribution to biotech in the past 10 years. Nature Biotechnology 24, 291-300, 2006
  • Xolair chosen for Prix Galien Award for outstanding innovation in R&D, UK, 2006
  • "Honorary Fellow Award" from American Academy of Allergy, Asthma, and Immunology (AAAAI), 2007
  • "Father of Xolair" plaque from Novartis, in Middle East Asthma and Allergy Conference, Dubai, 2012
  • "Lifetime Achievement Award in Allergy" from Taiwan Academy of Pediatric Allergy, Asthma and Clinical Immunology, 2013
  • TWAS(The World Academy of Sciences) Prize in Medical Sciences, 2014

RESEARCH INTERESTS:

New drug discovery and antibody engineering

The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.

research3

我們的研究主軸是利用抗體工程技術來開發新藥。這些以抗體為結構基礎的藥物,主要標的牽涉於IgE引致的過敏反應過程。我們也積極從事開發可提升抗體工程 的數種創新技術平台。其中一項研究計畫就是要發展人源化、高親和力,及對人體膜IgE分子內CεmX具結合特異性的抗體,以用來控制表現IgE的B淋巴細 胞。CεmX是張教授的研究群發現的;它是一含有具特異序列的52個氨基酸長的胜肽區段。如發展成功,anti-CεmX可與張教授發明的anti-IgE,如已在美國等國核准上市用於嚴重哮喘的omalizumab(商名Xolair),共同使用。

SELECTED PUBLICATIONS:

  • Lu CS, Hung AF, Lin CJ, Chen JB, Chen C, Shiung YY, Tsai CY, Chang TW, 2015, “Generating allergen-specific human IgEs for immunoassays by employing human epsilon gene knockin mice.”, Allergy, 70(4), 384-390. (SCIE)
  • Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C, 2015, “Structural and Physical Basis for Anti-IgE Therapy.”, Scientific reports, 5, 11581. (SCIE)
  • Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, “The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.”, The Journal of allergy and clinical immunology, 135(2), 337-342.e2. (SCIE)
  • Chang TW, 2014, “Changing patterns of antigen exposure and their impact on the prevalence of allergy.”, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 25(8), 733-739. (SCIE)
  • Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, “Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations.”, Nature communications, 5, 3139. (SCIE)
  • Chen NY, Hung AF, Lin CJ, Chen JB, Chu HM, Yu HM, Chang HY, Chang TW, 2013, “Manipulating mIgD-expressing B cells with anti-migis-delta monoclonal antibodies.”, Molecular immunology, 53(3), 187-197. (SCIE)
  • Chang TW*, Chen JB, Chu, CY , 2012, “The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis”, Dermatologica Sinica, 30(4), 147-153. (SCIE)
  • Shiung, Y.Y., Chiang, C.Y., Chen, J.B., Wu, P.C., Hung, A.F., Lu, D.C.S., Pan, R.L., and Chang, T.W. , 2012, “An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors”, Immunobiology, 217(7), 676-683. (SCIE)
  • Lin CJ, Chen NY, Chen JB, Lu CS, Hung AF, Shiung YY, Wu PC, Pan RL, Chang TW, 2012, “CvarepsilonmX peptide-carrying HBcAg virus-like particles induced antibodies that down-regulate mIgE-B lymphocytes.”, Molecular immunology, 52(3-4), 190-199. (SCIE)
  • Hung AF, Chen JB, Lu CS, Chen NY, Yu HM, Chang TW, 2011, “Lipid rafts hinder binding of antibodies to the extracellular segment of the membrane-anchor peptide of mIgA.”, Molecular immunology, 48(15-16), 1975-1982. (SCIE)
  • Wu PC, Chen JB, Kawamura S, Roos C, Merker S, Shih CC, Hsu BD, Lim C, Chang TW, 2011, “The IgE gene in primates exhibits extraordinary evolutionary diversity.”, Immunogenetics, 64(4), 279-287. (SCIE)
  • Hsu CL, Shiung YY, Lin BL, Chang HY, Chang TW, 2010, “Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model.”, International immunopharmacology, 10(4), 533-539. (SCIE)
  • Wan L, Chen JB, Chen HH, Huang J, Yu HM, Luo SF, Tsai FJ, Chang TW, 2010, “Genetic variations in the C epsilon mX domain of human membrane-bound IgE.”, Immunogenetics, 62(5), 273-280. (SCIE)
  • Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW, 2010, “Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.”, Journal of immunology, 184(4), 1748-1756. (SCIE)
  • A. F. Hung, J. B. Chen and T. W. Chang*, 2008, “Alleles and isoforms of human memebrane-bound IgA1”, Molecular Immunology, 45(13), 3624-3630. (SCIE)
  • Chang TW & Pan AY, 2008, “Cumulative environmental changes, skewed antigen exposure, and the increase of allergy.”, Advances in immunology, 98, 39-83. (SCIE)
  • Chang TW, Wu PC, Hsu CL, Hung AF, 2007, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.”, Advances in immunology, 93, 63-119. (SCIE)
  • Chang TW & Shiung YY, 2006, “Anti-IgE as a mast cell-stabilizing therapeutic agent.”, The Journal of allergy and clinical immunology, 117(6), 1203-1212. (SCIE)
  • T. W. Chang*, 2006, “Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E”, Allergy and Asthma Proceedings, 27(2 Suppl 1), S7-S14. (SCIE)
  • Lanier, B.Q., and Chang, T.W., 2004, “Will anti-IgE therapy compromise normal immune functions”, Allergy & Clinical Immunology International - Journal of the World Allergy Organization, 16, 237-240.
  • Sheu JJ, Cheng T, Chen HY, Lim C, Chang TW, 2003, “Comparative effects of human Ig alpha and Ig beta in inducing autoreactive antibodies against B cells in mice.”, Journal of immunology, 170(3), 1158-1166. (SCIE)
  • Wan L, Chen YH, Chang TW, 2003, “Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification.”, Journal of pharmaceutical sciences, 92(9), 1882-1892. (SCIE)
  • Huang J, Sheu JJ, Wu SC, Chang TW, 2002, “Down regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG.Fc fragment.”, Immunology letters, 81(1), 49-58. (SCIE)
  • Sheu JJ, Huang J, Chang TW, 2002, “Inducing specific reactivity against B cells in mice by immunizing with an Fc fusion protein containing self-Igbeta.”, Cancer Immunology Immunotherapy, 51(3), 145-152. (SCIE)
  • Chen HY, Liu FT, Hou CM, Huang JS, Sharma BB, Chang TW, 2002, “Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells.”, International archives of allergy and immunology, 128(4), 315-324. (SCIE)
  • Wan L, Chang TW, 2002, “Site-specific lipophilic modification of interferon-alpha.”, Journal of protein chemistry, 21(6), 371-381.
  • Fan Y, Wu CY, Chen CW, Chang TW, Lim C, 2001, “Preparing a human membrane and secreted protein-enriched cDNA library using PCR primers derived from a genomic database.”, Nucleic acids research, 29(22), E114. (SCIE)
  • Chang, T.W., 2001, “The IgE Story”, Pathways, 2, 26-29.
  • Chang TW, 2000, “The pharmacological basis of anti-IgE therapy.”, Nature biotechnology, 18(2), 157-162. (SCIE)
  • Schwarze J, Cieslewicz G, Joetham A, Sun LK, Sun WN, Chang TW, Hamelmann E, Gelfand EW, 1998, “Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice.”, American journal of respiratory and critical care medicine, 158(2), 519-525. (SCIE)
  • Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W, 1997, “Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis.”, Clinical pharmacology and therapeutics, 62(6), 675-690. (SCIE)
  • Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S, 1997, “The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.”, The Journal of clinical investigation, 99(5), 879-887. (SCIE)
  • Chen SS, Schmaltz R, Wang YY, Kong QX, Petro T, Li Q, Chang TW, 1996, “Inhibition of antigen-specific IgE production by antigen coupled to membrane IgE peptide.”, Immunological investigations, 25(5-6), 495-505. (SCIE)
  • Major JG Jr, Davis FM, Liou RS, Chang TW, 1996, “Structural features of the extracellular portion of membrane-anchoring peptides on membrane-bound immunoglobulins.”, Molecular immunology, 33(2), 179-187. (SCIE)
  • Sun LK, Fung MS, Sun WN, Sun CR, Chang WI, Chang TW, 1995, “Human IgA monoclonal antibodies specific for a major ragweed pollen antigen.”, Bio/technology (Nature Publishing Company), 13(8), 779-786.
  • Major JG, Liou RS, Sun LK, Yu LM, Starnes SM, Fung MS, Chang TW, Chang NT, 1994, “Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.”, Human antibodies and hybridomas, 5(1-2), 9-17.
  • Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J, et al., 1993, “Can anti-IgE be used to treat allergy?”, Springer seminars in immunopathology, 15(1), 51-73.
  • Safrit JT, Fung MS, Andrews CA, Braun DG, Sun WN, Chang TW, Koup RA, 1993, “hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.”, AIDS, 7(1), 15-21. (SCIE)
  • Wedrychowski A, Kim YW, Chang TW, 1993, “Immune enhancers composed of polyvalent binding sites of anti-CD3 antibodies.”, Bio/technology (Nature Publishing Company), 11(4), 486-489.
  • Chang TW, 1993, “Immunosorbent cytometry. A new technique for clinical leukocyte subset analysis.”, Bio/technology (Nature Publishing Company), 11(3), 291-293.
  • Schupbach J, Gunthard H, Fung MS, Liou RS, Botta L, Gowland P, Gordon W, Gygax D, Chang NT, Chang TW, et al., 1993, “Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease.”, Biotherapy (Dordrecht, Netherlands), 6(3), 205-215.
  • Braun DG, Fung MS, Chang NT, Chang TW, 1993, “Potential utility of passive immunization in preventing vertical HIV-1 transmission.”, Immunodeficiency, 4(1-4), 349-351.
  • Chang, T.W., Davis, F.M., Peng, C., and Chang, N.T., 1993, “Treating autoimmune diseases by isotype-specific suppression of antibodies”, Pharmaceutical Technology, 28-34.
  • Peng C, Davis FM, Sun LK, Liou RS, Kim YW, Chang TW, 1992, “A new isoform of human membrane-bound IgE.”, Journal of immunology, 148(1), 129-136. (SCIE)
  • Yu LM, Chang TW, 1992, “Human mb-1 gene: complete cDNA sequence and its expression in B cells bearing membrane Ig of various isotypes.”, Journal of immunology, 148(2), 633-637. (SCIE)
  • Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, Sun WN, Daar ES, Ho DD, 1992, “Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.”, Journal of virology, 66(2), 848-856. (SCIE)
  • Liou RS, Fung MS, Zuhlke U, Gudat F, McKinney S, Gordon W, Bee W, Botta L, Gygax D, Chang TW, et al., 1992, “Mouse/human chimeric anti-HIV-1 gp120 antibody to the principal neutralizing determinant: tolerability and pharmacokinetics in cynomolgus monkeys, Macaca fascicularis.”, Biotherapy (Dordrecht, Netherlands), 5(4), 291-299.
  • Kim YW, Chang TW, 1992, “Potential use of immunoconjugates for AIDS therapy.”, AIDS research and human retroviruses, 8(6), 1033-1038. (SCIE)
  • Davis FM, Gossett LA, Chang TW, 1991, “An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation.”, Bio/technology (Nature Publishing Company), 9(1), 53-56.
  • Ho DD, Fung MS, Cao YZ, Li XL, Sun C, Chang TW, Sun NC, 1991, “Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.”, Proceedings of the National Academy of Sciences of the United States of America, 88(20), 8949-8952. (SCIE)
  • Peng C, Chang NT, Chang TW, 1991, “Identification and characterization of human immunodeficiency virus type 1 gag-pol fusion protein in transfected mammalian cells.”, Journal of virology, 65(5), 2751-2756. (SCIE)
  • Sun LK, Liou RS, Sun NC, Gossett LA, Sun C, Davis FM, MacGlashan DW Jr, Chang TW, 1991, “Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity.”, Journal of immunology, 146(1), 199-205. (SCIE)
  • Kim YW, Fung MS, Sun NC, Sun CR, Chang NT, Chang TW, 1990, “Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1.”, Journal of immunology, 144(4), 1257-1262. (SCIE)
  • Fung MS, Sun CR, Liou RS, Gordon W, Chang NT, Chang TW, Sun NC, 1990, “Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.”, Journal of immunology, 145(7), 2199-2206. (SCIE)
  • Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW Jr, Hamilton RG, 1990, “Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases.”, Bio/technology (Nature Publishing Company), 8(2), 122-126.
  • Chang, T.W., 1990, “Monoclonal antibodies specific for IgE-secreting B lymphocytes”, ICSU Short Reports, 10, 188-189.
  • Vyas MN, Vyas NK, Liou RS, Chang TW, Quiocho FA, 1990, “Preliminary crystallographic analysis of the Fab fragment of an antibody against HIV gp120.”, Journal of molecular biology, 214(1), 23-24. (SCIE)
  • Yu LM, Peng C, Starnes SM, Liou RS, Chang TW, 1990, “Two isoforms of human membrane-bound alpha Ig resulting from alternative mRNA splicing in the membrane segment.”, Journal of immunology, 145(11), 3932-3936. (SCIE)
  • Liou RS, Rosen EM, Fung MS, Sun WN, Sun C, Gordon W, Chang NT, Chang TW, 1989, “A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.”, Journal of immunology, 143(12), 3967-3975. (SCIE)
  • Sun, N.S., Ho, D.D., Sun, C.R.Y., Liou, R.S., Gordon, W., Fung, M.S.C., Li, X.L., Lee, T.H., Chang, N.T., and Chang, T.W., 1989, “Generation and characterization of monoclonal antibodies to the putative CD-4 binding domain of HIV-1 gp120”, J. Virol., 63, 3579-3585. (SCIE)
  • Peng C, Ho BK, Chang TW, Chang NT, 1989, “Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.”, Journal of virology, 63(6), 2550-2556. (SCIE)
  • Fung MC, Chiu KY, Weber T, Chang TW, Chang NT, 1988, “Detection and purification of a recombinant human B lymphotropic virus (HHV-6) in the baculovirus expression system by limiting dilution and DNA dot-blot hybridization.”, Journal of virological methods, 19(1), 33-42. (SCIE)
  • Fung, M.S.C., Sun, C., Sun, N.C., Chang, N.T., and Chang, T.W., 1987, “Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells”, Bio/Technology, 5, 940-946.
  • Hao XS, Le JM, Vilcek J, Chang TW, 1986, “Determination of human T cell activity in response to allogeneic cells and mitogens. An immunochemical assay for gamma-interferon is more sensitive and specific than a proliferation assay.”, Journal of immunological methods, 92(1), 59-63. (SCIE)
  • Chanda PK, Chen GF, Baine Y, Leonard WJ, Greene WC, Chang TW, Chang NT, 1986, “Expression of human interleukin-2 receptor cDNA in E. coli.”, Biochemical and biophysical research communications, 141(2), 804-811. (SCIE)
  • Franchini G, Robert-Guroff M, Wong-Staal F, Ghrayeb J, Kato I, Chang TW, Chang NT, 1986, “Expression of the protein encoded by the 3' open reading frame of human T-cell lymphotropic virus type III in bacteria: demonstration of its immunoreactivity with human sera.”, Proceedings of the National Academy of Sciences of the United States of America, 83(14), 5282-5285. (SCIE)
  • Ghrayeb J, Kato I, McKinney S, Huang JJ, Chanda PK, Ho DD, Sarangadharan MG, Chang TW, Chang NT, 1986, “Human T-cell lymphotropic virus type III (HTLV-III) core antigens: synthesis in Escherichia coli and immunoreactivity with human sera.”, DNA (Mary Ann Liebert, Inc.), 5(2), 93-99.
  • Chang NT, Huang J, Ghrayeb J, McKinney S, Chanda PK, Chang TW, Putney S, Sarngadharan MG, Wong-Staal F, Gallo RC, 1985, “An HTLV-III peptide produced by recombinant DNA is immunoreactive with sera from patients with AIDS.”, Nature, 315(6015), 151-154. (SCIE)
  • Chang, T.W., Kato, I., McKinney, S., Chanda, P., Barone, A.D., Wong-Staal, F., Gallo, R.C., and Chang, N.T., 1985, “Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant Escherichia coli-derived viral antigenic peptide”, Bio/Technology, 3, 905-909.
  • Chang NT, Chanda PK, Barone AD, McKinney S, Rhodes DP, Tam SH, Shearman CW, Huang J, Chang TW, Gallo RC, et al., 1985, “Expression in Escherichia coli of open reading frame gene segments of HTLV-III.”, Science, 228(4695), 93-96. (SCIE)
  • Le J, Chang TW, Liu V, Yip YK, Vilcek J, 1985, “Monoclonal antibodies as structural probes for oligomeric human interferon-gamma.”, Journal of interferon research, 5(3), 445-453.
  • Chang, T.W., 1985, “Regulation of immune response by antibodies: the importance of antibody and monocyte Fc receptor interaction in T cell activation”, Immunology Today, 6, 245-249.
  • Celis E, Kato I, Miller RW, Chang TW, 1985, “Regulation of the human immune response to HBsAg: effects of antibodies and antigen conformation in the stimulation of helper T cells by HBsAg.”, Hepatology, 5(5), 744-751. (SCIE)
  • Celis E, Chang TW, Stricker L, Tiebout RF, Zeijlemaker WP, 1985, “Role for monoclonal hepatitis B antibody in hepatitis B immunisation programmes.”, Lancet, 1(8439), 1219. (SCIE)
  • Chang NT, Tam SH, Kung PC, Chang TW, 1984, “A cDNA clone encoding a product of activated human T lymphocytes.”, Molecular biology & medicine, 2(2), 151-165.
  • Celis E, Chang TW, 1984, “Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen.”, Science, 224(4646), 297-299. (SCIE)
  • Celis E, Miller RW, Chang TW, 1984, “Antigen-induced production of lymphokines by human T cell clones specific for hepatitis B surface antigen.”, Human immunology, 11(4), 229-237. (SCIE)
  • Celis E, Chang TW, 1984, “HBsAg-serum protein complexes stimulate immune T lymphocytes more efficiently than do pure HBsAg.”, Hepatology, 4(6), 1116-1123. (SCIE)
  • Celis E, Kung PC, Chang TW, 1984, “Hepatitis B virus-reactive human T lymphocyte clones: antigen specificity and helper function for antibody synthesis.”, Journal of immunology, 132(3), 1511-1516. (SCIE)
  • Chang TW, Celis E, Miller RW, Zurawski VR Jr, Kung PC, 1984, “In vitro response to HBsAg of peripheral blood lymphocytes from recipients of hepatitis B vaccine.”, Hepatology, 4(5), 824-829. (SCIE)
  • Kung, P.C., Chang, T.W., and Zurawski, Jr., V.R., 1984, “Monoclonal antibodies in clinical investigation”, Clinical Biochemistry : Contemporary Theories and Techniques, 3, 89-115. (SCIE)
  • Celis E, Zurawski VR Jr, Chang TW, 1984, “Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies.”, Proceedings of the National Academy of Sciences of the United States of America, 81(21), 6846-6850. (SCIE)
  • Chang TW, McKinney S, Liu V, Kung PC, Vilcek J, Le J, 1984, “Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon.”, Proceedings of the National Academy of Sciences of the United States of America, 81(16), 5219-5222. (SCIE)
  • Chang TW, 1983, “Binding of cells to matrixes of distinct antibodies coated on solid surface.”, Journal of immunological methods, 65(1-2), 217-223. (SCIE)
  • Wall KA, Frackelton AR Jr, Reilly EB, Azuma T, Chang TW, Eisen HN, 1983, “Quantitative of anti-NP (4-hydroxy-3-nitrophenyl)-acetyl idiotype expression on spleen and thymus cells.”, European journal of immunology, 13(6), 441-448. (SCIE)
  • Chang TW, Testa D, Kung PC, Perry L, Dreskin HJ, Goldstein G, 1982, “Cellular origin and interactions involved in gamma-interferon production induced by OKt3 monoclonal antibody.”, Journal of immunology, 128(2), 585-589. (SCIE)
  • Chang TW, 1982, “Induction of T cell proliferation and lymphokine production by monoclonal antibody.”, Lymphokine research, 1(1), 5-8.
  • Chang, T.W., 1982, “Monoclonal antibodies: preparation by hybridoma method and application in biological research”, Proceedings of Symposium and Workshops of Genetic Engineering, 263-281.
  • Chang, T.W. and Chang, N.T., 1982, “Workshop: production of monoclonal antibodies by hybridoma method”, Proceedings of Symposium and Workshops of Genetic Engineering, 263-281.
  • Chang TW, Kung PC, Gingras SP, Goldstein G, 1981, “Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?”, Proceedings of the National Academy of Sciences of the United States of America, 78(3), 1805-1808. (SCIE)
  • Chang TW, Gingras SP, 1981, “OKT3 monoclonal antibody inhibits cytotoxic T lymphocyte mediated cell lysis.”, International journal of immunopharmacology, 3(3), 183-186.
  • Chang, T.W. and Gingras S.P., 1981, “OKT3 monoclonal antibody inhibits cytotoxic T lymphocyte-mediated cell lysis”, International Journal of Immunopharmacology, 3(3), 183-186.
  • Kung, P.C., Talle, M.A., Lifter, J., Goldstein, G., and Chang, T.W., 1981, “Production of monoclonal antibody for clinical use”, Proc. Leukemia Markers Conf., 161-171.
  • Biddison WE, Shearer GM, Chang TW, 1981, “Regulation of influenza virus-specific cytotoxic T cell responses by monoclonal antibody to a human T cell differentiation antigen.”, Journal of immunology, 127(6), 2236-2240. (SCIE)
  • Chang TW, Eisen HN, 1980, “Effects of N alpha-tosyl-L-lysyl-chloromethylketone on the activity of cytotoxic T lymphocytes.”, Journal of immunology, 124(3), 1028-1033. (SCIE)
  • Azuma, T., Chang, T.W., Eisen, H.N., Frackelton, Jr., A.R., and Wall, K.A., 1980, “Lamda light chains and idiotype-bearing T cells”, Molecules, Cells and Parasites in Immunology., 65-74.
  • Chang TW, Celis E, Eisen HN, Solomon F, 1979, “Crawling movements of lymphocytes on and beneath fibroblasts in culture.”, Proceedings of the National Academy of Sciences of the United States of America, 76(6), 2917-2921. (SCIE)
  • Celis E, Chang TW, Eisen HN, 1979, “Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. III. Periodic production of a cell surface glycoprotein and changes in reactivity with cytotoxic T cells and anti-H-2d sera.”, Journal of immunology, 122(6), 2245-2250. (SCIE)
  • Chang TW, Eisen HN, 1979, “Lymphomas with cytotoxic activity.”, Nature, 280(5721), 406-408. (SCIE)
  • Chang TW, Goldberg AL, 1978, “A relationship between the rates of acetyl group oxidation and the oxygen consumption of cellls.”, The Journal of biological chemistry, 253(10), 3693-2695. (SCIE)
  • Chang TW, Goldberg AL, 1978, “Leucine inhibits oxidation of glucose and pyruvate in skeletal muscles during fasting.”, The Journal of biological chemistry, 253(10), 3696-3701. (SCIE)
  • Goldberg AL, Chang TW, 1978, “Regulation and significance of amino acid metabolism in skeletal muscle.”, Federation proceedings, 37(9), 2301-2307.
  • Goldberg, A.L., DeMartino, G.N., and Chang, T.W., 1978, “Release of gluconeogenic precursors from skeletal muscle”, FEBS Symposia, 42, 347-358.
  • Chang TW, Goldberg AL, 1978, “The metabolic fates of amino acids and the formation of glutamine in skeletal muscle.”, The Journal of biological chemistry, 253(10), 3685-3693. (SCIE)
  • Chang TW, Goldberg AL, 1978, “The origin of alanine produced in skeletal muscle.”, The Journal of biological chemistry, 253(10), 3677-3684. (SCIE)
  • Wong, C., Lee, T.Y., Lee, T.J., Chang, T.W., and Lieu, C.H, 1973, “Novel structure of berrylocene”, Inorg. Nucl. Chem. Letters, 9, 667-673.
  • Chang TW, Tang N, 1972, “Selection pressures on homologous proteins of varied activities.”, Nature: New biology, 239(94), 207. (SCIE)
  • Wong CH, Chang TW, Lee TJ, 1972, “X-ray crystallographic study of cobrotoxin.”, The Journal of biological chemistry, 247(2), 608. (SCIE)
  • T. W. Chang*, P. C. Wu, C. L. Hsu and A. F. Hung, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases”, Advances in Immunology, pp. 63-119, San Diego, CA: Elsevier Academic Press Inc.